Transcode Therapeutics Stock Price Prediction

RNAZ Stock  USD 0.38  0.04  11.56%   
At this time, the RSI of Transcode Therapeutics' share price is approaching 42 indicating that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Transcode Therapeutics, making its price go up or down.

Oversold Vs Overbought

42

 
Oversold
 
Overbought
The successful prediction of Transcode Therapeutics' future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Transcode Therapeutics, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Transcode Therapeutics' stock price prediction:
EPS Estimate Next Quarter
(0.19)
EPS Estimate Current Year
(1.84)
EPS Estimate Next Year
(0.46)
Wall Street Target Price
3
EPS Estimate Current Quarter
(0.49)
Using Transcode Therapeutics hype-based prediction, you can estimate the value of Transcode Therapeutics from the perspective of Transcode Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Transcode Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Transcode because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Transcode Therapeutics after-hype prediction price

    
  USD 0.43  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Transcode Therapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.
Intrinsic
Valuation
LowRealHigh
0.163.2815.37
Details
Naive
Forecast
LowNextHigh
0.010.3612.45
Details
1 Analysts
Consensus
LowTargetHigh
10.9212.0013.32
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.46-0.46-0.46
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Transcode Therapeutics. Your research has to be compared to or analyzed against Transcode Therapeutics' peers to derive any actionable benefits. When done correctly, Transcode Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Transcode Therapeutics.

Transcode Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Transcode Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Transcode Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Transcode Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Transcode Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Transcode Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Transcode Therapeutics' historical news coverage. Transcode Therapeutics' after-hype downside and upside margins for the prediction period are 0.02 and 12.52, respectively. We have considered Transcode Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
0.38
0.43
After-hype Price
12.52
Upside
Transcode Therapeutics is dangerous at this time. Analysis and calculation of next after-hype price of Transcode Therapeutics is based on 3 months time horizon.

Transcode Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Transcode Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Transcode Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Transcode Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  1.11 
12.18
  0.04 
  0.08 
2 Events / Month
10 Events / Month
In a few days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
0.38
0.43
13.37 
30,450  
Notes

Transcode Therapeutics Hype Timeline

Transcode Therapeutics is at this time traded for 0.38. The entity has historical hype elasticity of 0.04, and average elasticity to hype of competition of 0.08. Transcode is forecasted to increase in value after the next headline, with the price projected to jump to 0.43 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 13.37%, whereas the daily expected return is at this time at 1.11%. The volatility of related hype on Transcode Therapeutics is about 16698.39%, with the expected price after the next announcement by competition of 0.46. Transcode Therapeutics currently holds 450.57 K in liabilities. Transcode Therapeutics has a current ratio of 7.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Transcode Therapeutics' use of debt, we should always consider it together with its cash and equity.Given the investment horizon of 90 days the next forecasted press release will be in a few days.
Check out Transcode Therapeutics Basic Forecasting Models to cross-verify your projections.
For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

Transcode Therapeutics Related Hype Analysis

Having access to credible news sources related to Transcode Therapeutics' direct competition is more important than ever and may enhance your ability to predict Transcode Therapeutics' future price movements. Getting to know how Transcode Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Transcode Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
LABPLandos Biopharma(0.20)1 per month 3.81  0.1  8.58 (7.05) 19.47 
NEXINeximmune 0.00 0 per month 0.00 (0.04) 5.90 (9.00) 94.30 
ONCROncorus 0.01 3 per month 0.00 (0.16) 10.00 (21.20) 120.67 
XBIOXenetic Biosciences 0.10 6 per month 4.50 (0.0002) 7.65 (7.27) 26.99 
RVPHWReviva Pharmaceuticals Holdings 0.02 2 per month 17.17  0.09  28.57 (33.33) 129.53 
EYENEyenovia 0.01 10 per month 0.00 (0.16) 11.76 (19.61) 92.81 
CGTXCognition Therapeutics 0.04 8 per month 0.00 (0.12) 8.89 (10.34) 36.32 
KODKodiak Sciences 0.12 5 per month 2.84  0.27  9.70 (4.92) 18.79 
IMMXImmix Biopharma(0.11)5 per month 0.00 (0.04) 7.06 (8.22) 32.68 
CNSPCns Pharmaceuticals(0.01)6 per month 0.00 (0.05) 9.09 (11.76) 39.29 
EFTREffector Therapeutics(0.06)4 per month 0.00 (0.31) 8.70 (27.78) 88.91 
NAVBNavidea Biopharmaceuticals 0.00 0 per month 0.00 (0.14) 12.50 (12.50) 40.40 
SONNSonnet Biotherapeutics Holdings 1.15 7 per month 0.00 (0.13) 12.31 (9.79) 37.58 
REVBRevelation Biosciences(0.03)2 per month 7.23  0.02  10.53 (9.01) 141.15 
ZURAZura Bio Limited 0.03 9 per month 0.00 (0.05) 7.95 (7.94) 30.69 
PHIOPhio Pharmaceuticals Corp 0.18 6 per month 0.00 (0.05) 11.78 (10.38) 36.22 
ZVSAZyVersa Therapeutics(0.01)5 per month 0.00 (0.14) 9.17 (10.36) 78.93 

Transcode Therapeutics Additional Predictive Modules

Most predictive techniques to examine Transcode price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Transcode using various technical indicators. When you analyze Transcode charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Transcode Therapeutics Predictive Indicators

The successful prediction of Transcode Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Transcode Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Transcode Therapeutics based on analysis of Transcode Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Transcode Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Transcode Therapeutics's related companies.
 2010 2023 2024 (projected)
Payables Turnover0.02110.02040.0175
Days Of Inventory On Hand2.1K1.8K1.6K

Story Coverage note for Transcode Therapeutics

The number of cover stories for Transcode Therapeutics depends on current market conditions and Transcode Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Transcode Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Transcode Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Transcode Therapeutics Short Properties

Transcode Therapeutics' future price predictability will typically decrease when Transcode Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Transcode Therapeutics often depends not only on the future outlook of the potential Transcode Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Transcode Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding179 K
Cash And Short Term Investments2.8 M

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.